BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013; 19(47): 8822-8830 [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822]
URL: https://www.wjgnet.com/1007-9327/full/v19/i47/8822.htm
Number Citing Articles
1
Yuanyuan Liu, Vaishnavi Veeraraghavan, Monica Pinkerton, Jianjun Fu, Mark W. Douglas, Jacob George, Thomas Tu. Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and RecurrenceFrontiers in Microbiology 2021; 12 doi: 10.3389/fmicb.2021.665201
2
Yinghua Zhang, Chuanfang Wang, Hui Li, Yuanyuan Ding. Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis BMedicine 2019; 98(3): e13929 doi: 10.1097/MD.0000000000013929
3
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II RecommendationsJournal of Clinical and Experimental Hepatology 2020; 10(1): 43 doi: 10.1016/j.jceh.2019.09.007
4
George V. Papatheodoridis, Ramazan Idilman, George N. Dalekos, Maria Buti, Heng Chi, Florian van Boemmel, Jose Luis Calleja, Vana Sypsa, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Onur Keskın, Nikolaos Gatselis, Bettina E. Hansen, Maria Lehretz, Juan de la Revilla, Savvoula Savvidou, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis BHepatology 2017; 66(5): 1444 doi: 10.1002/hep.29320
5
Dan-Hong Yang, Wei-Ping Wang, Qiang Zhang, Hong-Ying Pan, Yi-Cheng Huang, Jia-Jie Zhang. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional studyWorld Journal of Gastroenterology 2021; 27(17): 2025-2038 doi: 10.3748/wjg.v27.i17.2025
6
Kung-Hao Liang, Chao-Wei Hsu, Ming-Ling Chang, Yi-Cheng Chen, Ming-Wei Lai, Chau-Ting Yeh. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis BJournal of Infectious Diseases 2016; 213(6): 966 doi: 10.1093/infdis/jiv547
7
Yong-Wei Li, Feng-Cai Yang, Hui-Qiong Lu, Jiong-Shan Zhang. Hepatocellular carcinoma and hepatitis B surface proteinWorld Journal of Gastroenterology 2016; 22(6): 1943-1952 doi: 10.3748/wjg.v22.i6.1943
8
Evangelos Cholongitas, Ioannis Goulis, Nikolaos Antoniadis, Ioannis Fouzas, George Imvrios, Vasilios Papanikolaou, Evangelos Akriviadis. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrenceTransplant International 2014; 27(10): 1022 doi: 10.1111/tri.12370
9
Alkistis Papatheodoridi, Antonios Chatzigeorgiou, Lampros Chrysavgis, Panagiotis Lembessis, Alessandro Loglio, Floriana Facchetti, Evangelos Cholongitas, Michael Koutsilieris, Pietro Lampertico, George Papatheodoridis. Circulating cell‐free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patientsJournal of Viral Hepatitis 2021; 28(3): 464 doi: 10.1111/jvh.13446
10
Walid S. Ayoub, Paul Martin, Pietro Lampertico. Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?Current Hepatology Reports 2015; 14(4): 279 doi: 10.1007/s11901-015-0279-1
11
Jiannis Vlachogiannakos, George V. Papatheodoridis. Hepatitis B: Who and when to treat?Liver International 2018; 38: 71 doi: 10.1111/liv.13631
12
Mi Na Kim, Seong Gyu Hwang, Kyu Sung Rim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovirLiver International 2017; 37(12): 1788 doi: 10.1111/liv.13450
13
Lihu Gu, Qigu Yao, Zefeng Shen, Ying He, Derry Minyao Ng, Tong Yang, Bangsheng Chen, Ping Chen, Feiyan Mao, Qili Yu. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis Journal of Gastroenterology and Hepatology 2020; 35(9): 1467 doi: 10.1111/jgh.15036
14
Jiannis Vlachogiannakos, George V. Papatheodoridis. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?Liver International 2015; 35: 100 doi: 10.1111/liv.12719
15
Alberto Ferrarese, Alberto Zanetto, Martina Gambato, Ilaria Bortoluzzi, Elena Nadal, Giacomo Germani, Marco Senzolo, Patrizia Burra, Francesco Paolo Russo. Liver transplantation for viral hepatitis in 2015World Journal of Gastroenterology 2016; 22(4): 1570-1581 doi: 10.3748/wjg.v22.i4.1570
16
George Papatheodoridis, George Dalekos, Vana Sypsa, Cihan Yurdaydin, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis, Onur Keskin, Savvoula Savvidou, Juan de la Revilla, Bettina E. Hansen, Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyJournal of Hepatology 2016; 64(4): 800 doi: 10.1016/j.jhep.2015.11.035
17
George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Cihan Yurdaydin, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BJournal of Hepatology 2020; 73(5): 1037 doi: 10.1016/j.jhep.2020.06.011
18
Jiannis Vlachogiannakos, George V. Papatheodoridis. HBV: Do I treat my immunotolerant patients?Liver International 2016; 36: 93 doi: 10.1111/liv.12996
19
George V. Papatheodoridis, Vana Sypsa, George Dalekos, Cihan Yurdaydin, Florian van Boemmel, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Nikolaos Gatselis, Onur Keskın, Maria Lehretz, Savvoula Savvidou, Juan de la Revilla, Bettina E. Hansen, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general populationJournal of Hepatology 2018; 68(6): 1129 doi: 10.1016/j.jhep.2018.01.031
20
George V. Papatheodoridis, George N. Dalekos, Cihan Yurdaydin, Maria Buti, John Goulis, Pauline Arends, Vana Sypsa, Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis, Onur Keskın, Savvoula Savvidou, Bettina E. Hansen, Christos Papaioannou, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovirJournal of Hepatology 2015; 62(2): 363 doi: 10.1016/j.jhep.2014.08.045
21
Yuanyuan Sun, Yanhong Wang, Mengmeng Li, Kailiang Cheng, Xinyu Zhao, Yuan Zheng, Yan Liu, Shaoyuan Lei, Li Wang. Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysisBMJ Open 2018; 8(2): e020490 doi: 10.1136/bmjopen-2017-020490
22
George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Cihan Yurdaydin, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis BJHEP Reports 2021; 3(3): 100290 doi: 10.1016/j.jhepr.2021.100290
23
Kyu Sik Jung, Seung Up Kim, Kijun Song, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Kwang-Hyub Han. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapyHepatology 2015; 62(6): 1757 doi: 10.1002/hep.28115
24
Brianna J Shinn, Aaron Martin, Robert M Coben, Mitchell I Conn, Jorge Prieto, Howard Kroop, Anthony J DiMarino, Hie-Won Hann. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cureWorld Journal of Hepatology 2019; 11(1): 65-73 doi: 10.4254/wjh.v11.i1.65
25
George V. Papatheodoridis, Vana Sypsa, George N. Dalekos, Cihan Yurdaydin, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, Heng Chi, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Theodoros Voulgaris, Nikolaos Gatselis, Onur Keskin, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Ramazan Idilman, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis BJournal of Hepatology 2020; 72(6): 1088 doi: 10.1016/j.jhep.2020.01.007
26
Peipei Ren, Zhujun Cao, Ruidong Mo, Yuhan Liu, Lichang Chen, Ziqiang Li, Tianhui Zhou, Jie Lu, Yunye Liu, Qing Guo, Rong Chen, Huijuan Zhou, Xiaogang Xiang, Wei Cai, Hui Wang, Shisan Bao, Yumin Xu, Honglian Gui, Qing Xie. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high riskExpert Opinion on Biological Therapy 2018; 18(10): 1085 doi: 10.1080/14712598.2018.1518423
27
Hye Won Lee, Sang Hoon Ahn. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patientsWorld Journal of Gastroenterology 2016; 22(37): 8314-8321 doi: 10.3748/wjg.v22.i37.8314